Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

NCT06446726 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Tislelizumab
RADIATION: Low-dose radiotherapy
DRUG: Nab-paclitaxel
DRUG: Cisplatin

Sponsor

Sichuan University